Volume 15, Number 8—August 2009
Research
Increase in Pneumococcus Macrolide Resistance, United States
Stephen G. Jenkins
and David J. Farrell
and David J. Farrell
Table 1
Erythromycin resistance among Streptococcus pneumoniae isolates, year 5 (2004–2005) and year 6 (2005–2006) of the PROTEKT US surveillance study*
| US region† | Isolates, no. resistant/no. submitted (%) |
|
|---|---|---|
| Year 5 | Year 6 | |
| Northeast | 518/1,931 (26.8) | 662/2,102 (31.5) |
| North Central | 467/1,314 (35.5) | 568/1,395 (40.7) |
| Northwest | 94/417 (22.5) | 108/422 (25.6) |
| Southeast | 340/998 (34.1) | 419/1,064 (39.4) |
| South Central | 402/1,149 (35.0) | 529/1,368 (38.7) |
| Southwest | 86/448 (19.2) | 95/396 (24.0) |
| Total | 1,907/6,257 (30.5) | 2,381/6,747 (35.3) |
*PROTEKT US, Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin, United States.
†States submitting isolates for testing included Northeast: CT, DE, IN, MA, MD, MI, NJ, NY, OH, PA, RI, VT, and DC; North Central: IA, IL, KS, MN, MD, ND, NE, SD, and WI; Northwest: AK, ID, MT, OR, WA, and WY; Southeast: FL, GA, KY, NC, SC, VA, and WV; South Central: AL, AR, LA, OK, TN, and TX; Southwest: AZ, CA, CO, NM, NV, and UT.
Page created: September 07, 2012
Page updated: September 07, 2012
Page reviewed: September 07, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.